Warning: mail() has been disabled for security reasons in /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php on line 110

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-content/plugins/bigcontact/BigContact.php on line 43

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-includes/feed-rss2.php on line 8
Pain Therapeutics – US Market Buzz http://www.usmarketbuzz.com Nation and Economy Mon, 20 Jul 2020 16:28:22 +0000 en-US hourly 1 https://wordpress.org/?v=4.9.23 Traders Stocks Alert: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Portola Pharmaceuticals Inc (NASDAQ:PTLA), Pain Therapeutics, Inc. (NASDAQ:PTIE) http://www.usmarketbuzz.com/traders-stocks-alert-agios-pharmaceuticals-inc-nasdaqagio-portola-pharmaceuticals-inc-nasdaqptla-pain-therapeutics-inc-nasdaqptie-2493 Thu, 18 Dec 2014 13:44:06 +0000 http://www.usmarketbuzz.com/?p=2493 Lakeway, NY — (MARKET NEWS CALL) — 12/18/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Pain Therapeutics, Inc. (NASDAQ:PTIE), Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Portola Pharmaceuticals Inc (NASDAQ:PTLA).

Pain Therapeutics, Inc. (NASDAQ:PTIE)’s stock jumped 8.02% to $2.02. On November 14, 2014, the Compensation Committee of the Board of Directors of Pain Therapeutics, Inc. approved changes in compensation for the Company’s named executive officers.

Should Investors Buy PTIE After The Recent Development? Find Out Here

On November 14, 2014, the Committee determined that cash bonus payments would not be paid for 2014. The Committee also terminated performance-related goals set in 2012 and tied to filing of a New Drug Application of either (a) hydrocodone or (b) either hydromorphone or oxymorphone. Had these goals been met prior to termination, Remi Barbier, Chairman of the Board, President and Chief Executive Officer would have received $400,000, Nadav Friedmann, Ph.D., M.D., Chief Medical and Operating Officer would have received $200,000 and Peter S. Roddy, Vice President and Chief Financial Officer would have received $50,000.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s shares jumped 8.01% to $116.08. The company on Dec. 16 announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 297,968 shares at the public offering price of $110.75 per share. The exercise of the over-allotment option brought the total number of shares of common stock sold by Agios to 2,284,423 shares and increased the amount of gross proceeds raised in the offering, before underwriting discounts and estimated expenses of the offering, to approximately $253 million.

Is AGIO Going To Rise or Fall After Today’s Price Action? Find Out Here

Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares gained 8% to $29.56. Portola Pharmaceuticals (PTLA), Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) on Nov. 17 announced results from the first part of the Phase 3 ANNEXA(TM)-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors — Apixaban) studies. Andexanet alfa produced rapid and nearly complete reversal (by approximately 94 percent, p value < 0.0001) of the anticoagulant effect of Eliquis (apixaban) in healthy volunteers ages 50-75. The full data set will be presented today in an oral presentation during the “Clinical Science: Special Reports” session at the American Heart Association (AHA) 2014 Scientific Sessions in Chicago, IL.

Can Traders Buy PTLA After The Solid Rally? Get Free Trend Analysis Here

About thenextbigtrade.com

thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.

Disclaimer

The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.

]]>